GliaPharm

company

About

GliaPharm is a Swiss-based biotechnology company that develops treatments for neurological and psychiatric disorders.

  • 11 - 50

Details

Last Funding Type
Seed
Last Funding Money Raised
Fr2M
Industries
Biotechnology,Health Care
Founded date
Jan 1, 2016
Number Of Employee
11 - 50
Operating Status
Active

GliaPharm is a Swiss-based biotechnology company that offers treatments for neurological and psychiatric disorders.

GliaPharm's innovative therapeutic approach is to target glial cells , the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Their vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.

GliaPharm is a Swiss biotechnology company active in the development of treatments for neurological and psychiatric diseases.

The innovative therapeutic approach of GliaPharm is to target glial cells , or 'support cells' of neurons, to support and improve brain metabolism under certain pathological conditions. Their vision is to become a leader in the development of glial cell targeting agents that act as neuroprotective agents and maintain cognitive functions.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Fr2M
GliaPharm has raised a total of Fr2M in funding over 2 rounds. Their latest funding was raised on May 26, 2020 from a Seed round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 26, 2020 Seed Fr2M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
GliaPharm is funded by 2 investors. Gliaven and ACE & Company are the most recent investors.
Investor Name Lead Investor Funding Round
Gliaven Seed
ACE & Company Seed